Benitec Biopharma has developed a breakthrough platform for treating human diseases called ddRNAi.
Unlike other RNAi-based technologies, ddRNAi effects lasting change in target cells, leading to long term benefit and, potentially, cure.
All ASX Announcements
TT-034 CLINICAL TRIAL
Review 2 posters presented by Benitec at The Liver Meeting held on Nov 13-17, 2015 1. TT-034 Clinical Trial Update and 2. Toxicology Evaluation and Benitec's definition of efficacy